{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:57:43Z","timestamp":1789945063826,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001475","name":"Nanyang Technological University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001475","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council"},{"name":"TARIPH"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ijpharm.2019.01.062","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T11:56:01Z","timestamp":1549281361000},"page":"382-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis"],"prefix":"10.1016","volume":"559","author":[{"given":"The-Thien","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Vidaillac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Y.H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Abisheganaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-7607","authenticated-orcid":false,"given":"Sanjay H.","family":"Chotirmall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunn","family":"Hadinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2019.01.062_b0005","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.rmed.2009.11.014","article-title":"Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions","volume":"104","author":"Abdelrahim","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejps.2010.03.020","article-title":"Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease","volume":"40","author":"Adi","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1183\/20734735.021014","article-title":"Inhaled therapy in cystic fibrosis: agents, devices and regimens","volume":"11","author":"Agent","year":"2015","journal-title":"Breathe"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0020","first-page":"51","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0025","first-page":"2","article-title":"Patients' practices and experiences of using nebuliser therapy in the management of COPD at home","volume":"Res","author":"Alhaddad","year":"2015","journal-title":"BMJ Open Respir."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0030","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/AAC.02764-13","article-title":"A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus","volume":"58","author":"Barber","year":"2014","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcf.2016.10.001","article-title":"The fate of inhaled antibiotics after deposition in cystic fibrosis: how to get drug to the bug?","volume":"16","author":"Bos","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/jamp.2015.1220","article-title":"Effect of flow rate on in vitro aerodynamic performance of NEXThaler (R) in comparison with Diskus (R) and Turbohaler (R) dry powder inhalers","volume":"29","author":"Buttini","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0050","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives","volume":"6","author":"Chalmers","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41533-017-0019-9","article-title":"Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults","volume":"27","author":"Chalmers","year":"2017","journal-title":"NPJ Primary Care Respir. Med."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1166\/jbn.2010.1116","article-title":"Antibacterial efficacy of inhalable antibiotic-encapsulated biodegradable polymeric nanoparticles against E. coli biofilm cells","volume":"6","author":"Cheow","year":"2010","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0070","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jcis.2011.10.011","article-title":"Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility","volume":"367","author":"Cheow","year":"2012","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0629-1","article-title":"Bronchiectasis: an emerging global epidemic","volume":"18","author":"Chotirmall","year":"2018","journal-title":"BMC Pulm. Med"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0080","first-page":"51","article-title":"RESPIRE: breathing new life into bronchiectasis","author":"Chotirmall","year":"2018","journal-title":"Eur. Respir. J"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0085","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1378\/chest.09-2996","article-title":"Sputum candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis","volume":"138","author":"Chotirmall","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/jamp.2015.1241","article-title":"Aerosol performance and stability of liposomes containing ciprofloxacin nanocrystals","volume":"28","author":"Cipolla","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jamp.2011.0916","article-title":"Aerosol deposition in health and disease","volume":"25","author":"Darquenne","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21678707.2016.1196129","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"4","author":"De Soyza","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0110","first-page":"51","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jamp.2017.1415","article-title":"The rationale and evidence for use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis","volume":"31","author":"Dhand","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0120","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0125","doi-asserted-by":"crossref","unstructured":"Franze, S., Selmin, F., Samaritani, E., Minghetti, P., Cilurzo, F., 2018. Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging. Pharmaceutics 10.","DOI":"10.3390\/pharmaceutics10030139"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0130","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/AAC.02818-14","article-title":"Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin","volume":"58","author":"Gontijo","year":"2014","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0135","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1586\/14787210.2014.952282","article-title":"Antimicrobial treatment of non-cystic fibrosis bronchiectasis","volume":"12","author":"Grimwood","year":"2014","journal-title":"Expert Rev. Anti Infect Ther."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0140","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s11095-013-1280-4","article-title":"Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules","volume":"31","author":"Groo","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0145","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.colsurfb.2014.02.032","article-title":"Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa","volume":"116","author":"Hadinoto","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0150","article-title":"Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic pseudomonas AerugINOSa infection: results from two parallel phase iii trials (orbit-3 And-4)","volume":"195","author":"Haworth","year":"2017","journal-title":"Am. J. Respir. Crit. Care"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/17425247.2011.553219","article-title":"Stabilization of liposomes during drying","volume":"8","author":"Ingvarsson","year":"2011","journal-title":"Expert Opin. Drug Del."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI11154","article-title":"Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH","volume":"107","author":"Jayaraman","year":"2001","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0165","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1753465813487412","article-title":"Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis","volume":"7","author":"Justo","year":"2013","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2015.02.057","article-title":"Preserving the supersaturation generation capability of amorphous drug-polysaccharide nanoparticle complex after freeze drying","volume":"484","author":"Kiew","year":"2015","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0175","doi-asserted-by":"crossref","DOI":"10.3791\/3857","article-title":"Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung","author":"Kirchner","year":"2012","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0180","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.nano.2014.08.004","article-title":"In vivo toxicity of cationic micelles and liposomes","volume":"11","author":"Knudsen","year":"2015","journal-title":"Nanomed.-Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0185","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1002\/jps.21786","article-title":"Cryoprotectants for freeze drying of drug nano-suspensions: effect of freezing rate","volume":"98","author":"Lee","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jamp.2017.1377","article-title":"Model calculations of regional deposition and disposition for single doses of inhaled liposomal and dry powder ciprofloxacin","volume":"31","author":"Martin","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0195","first-page":"18","article-title":"Inhaled antibiotic therapy in chronic respiratory diseases","author":"Maselli","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0200","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","article-title":"Non-cystic fibrosis bronchiectasis","volume":"188","author":"McShane","year":"2013","journal-title":"Am. J. Respir. Crit. Care"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2013.06.024","article-title":"In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation","volume":"86","author":"Ong","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tiv.2016.08.002","article-title":"In vitro toxicity of cationic micelles and liposomes in cultured human hepatocyte (HepG2) and lung epithelial (A549) cell lines","volume":"36","author":"Roursgaard","year":"2016","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0215","first-page":"3","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","author":"Schneider","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0220","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","author":"Smiths","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0225","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/17425247.2015.1078309","article-title":"Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives","volume":"13","author":"Sugianto","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0235","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","article-title":"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles","volume":"30","author":"Suk","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2019.01.062_b0240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2005.09.010","article-title":"Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery","volume":"305","author":"Sweeney","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0245","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijpharm.2018.06.017","article-title":"A new therapeutic avenue for bronchiectasis: dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart","volume":"547","author":"Tran","year":"2018","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0250","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P-aeruginosa lung infections","volume":"117","author":"Tureli","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0255","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijpharm.2016.10.025","article-title":"Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: design of experiments approach","volume":"515","author":"Tureli","year":"2016","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy \u2013 barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0265","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013","volume":"14","author":"Weycker","year":"2017","journal-title":"Chron. Respir. Dis."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0270","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rmed.2016.06.007","article-title":"Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"117","author":"Wilson","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0275","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","article-title":"Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model","volume":"108","author":"Yang","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijpharm.2019.01.062_b0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2015.12.072","article-title":"Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: spray drying versus spray freeze drying preparation","volume":"499","author":"Yu","year":"2016","journal-title":"Int. J. Pharmaceut."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517319301036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517319301036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T17:37:19Z","timestamp":1565199439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517319301036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":56,"alternative-id":["S0378517319301036"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2019.01.062","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2019.01.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}